Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Feb 22, 2023 2:01pm
111 Views
Post# 35298887

RE:RE:Causing Implausible Speculation, With No Responsibilty

RE:RE:Causing Implausible Speculation, With No Responsibilty
homerun2010 wrote: Bet on the jockey not the horse
We have no jockey


There was actually no horse. We know Rathjen can ride a horse to victory. We've seen it with Carina which has raised significant institutional money and has received the 'green light' for human clinical trials.We know that BTI has a platform of value as validated by the US$200 million in potential milestone payments plus royalties to multiple parties, the J&J option, and that Cresence and Midatech valued the technology after due diligence. Ladenberg Thalmann and Armistice Capital also value xB3. 

BTI has simply needed a horse to ride. Herceptin was a dead-end. BTI hasn't had money. It takes time to give birth to a new horse and Rathjen is at it. Lysosomal Storage, neuroinflammation, and neurodegeneration is the strategic focus and is validated by Chiesi. Rathjen aimed very big with Biodexa which was validated by Armistice.This company needs a complete recapitaliztion. It needs $US10 million to start moving forward. At $.02 it can be done. Raise as much as possible!  
<< Previous
Bullboard Posts
Next >>